These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 29955381)

  • 1. Long-term use of adalimumab as monotherapy after attainment of low disease activity with adalimumab plus methotrexate in patients with rheumatoid arthritis.
    Keystone EC; Breedveld FC; Kupper H; Li Y; Florentinus S; Sainsbury I
    RMD Open; 2018; 4(1):e000637. PubMed ID: 29955381
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adjustment of therapy in rheumatoid arthritis on the basis of achievement of stable low disease activity with adalimumab plus methotrexate or methotrexate alone: the randomised controlled OPTIMA trial.
    Smolen JS; Emery P; Fleischmann R; van Vollenhoven RF; Pavelka K; Durez P; Guérette B; Kupper H; Redden L; Arora V; Kavanaugh A
    Lancet; 2014 Jan; 383(9914):321-32. PubMed ID: 24168956
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predictors of disease activity and structural progression after treatment with adalimumab plus methotrexate or continued methotrexate monotherapy in patients with early rheumatoid arthritis and suboptimal response to methotrexate.
    Smolen JS; van Vollenhoven RF; Florentinus S; Chen S; Suboticki JL; Kavanaugh A
    Ann Rheum Dis; 2018 Nov; 77(11):1566-1572. PubMed ID: 30076156
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Longterm effect of delaying combination therapy with tumor necrosis factor inhibitor in patients with aggressive early rheumatoid arthritis: 10-year efficacy and safety of adalimumab from the randomized controlled PREMIER trial with open-label extension.
    Keystone EC; Breedveld FC; van der Heijde D; Landewé R; Florentinus S; Arulmani U; Liu S; Kupper H; Kavanaugh A
    J Rheumatol; 2014 Jan; 41(1):5-14. PubMed ID: 24241487
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical, functional and radiographic consequences of achieving stable low disease activity and remission with adalimumab plus methotrexate or methotrexate alone in early rheumatoid arthritis: 26-week results from the randomised, controlled OPTIMA study.
    Kavanaugh A; Fleischmann RM; Emery P; Kupper H; Redden L; Guerette B; Santra S; Smolen JS
    Ann Rheum Dis; 2013 Jan; 72(1):64-71. PubMed ID: 22562973
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Testing treat-to-target outcomes with initial methotrexate monotherapy compared with initial tumour necrosis factor inhibitor (adalimumab) plus methotrexate in early rheumatoid arthritis.
    Kavanaugh A; van Vollenhoven RF; Fleischmann R; Emery P; Sainsbury I; Florentinus S; Chen S; Guérette B; Kupper H; Smolen JS
    Ann Rheum Dis; 2018 Feb; 77(2):289-292. PubMed ID: 29146743
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Less radiographic progression with adalimumab plus methotrexate versus methotrexate monotherapy across the spectrum of clinical response in early rheumatoid arthritis.
    Emery P; Genovese MC; van Vollenhoven R; Sharp JT; Patra K; Sasso EH
    J Rheumatol; 2009 Jul; 36(7):1429-41. PubMed ID: 19369462
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Disease activity, physical function, and radiographic progression after longterm therapy with adalimumab plus methotrexate: 5-year results of PREMIER.
    van der Heijde D; Breedveld FC; Kavanaugh A; Keystone EC; Landewé R; Patra K; Pangan AL
    J Rheumatol; 2010 Nov; 37(11):2237-46. PubMed ID: 20889601
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Head-to-head comparison of certolizumab pegol versus adalimumab in rheumatoid arthritis: 2-year efficacy and safety results from the randomised EXXELERATE study.
    Smolen JS; Burmester GR; Combe B; Curtis JR; Hall S; Haraoui B; van Vollenhoven R; Cioffi C; Ecoffet C; Gervitz L; Ionescu L; Peterson L; Fleischmann R
    Lancet; 2016 Dec; 388(10061):2763-2774. PubMed ID: 27863807
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The PREMIER study: A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment.
    Breedveld FC; Weisman MH; Kavanaugh AF; Cohen SB; Pavelka K; van Vollenhoven R; Sharp J; Perez JL; Spencer-Green GT
    Arthritis Rheum; 2006 Jan; 54(1):26-37. PubMed ID: 16385520
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and efficacy of switching from adalimumab to sarilumab in patients with rheumatoid arthritis in the ongoing MONARCH open-label extension.
    Burmester GR; Strand V; Rubbert-Roth A; Amital H; Raskina T; Gómez-Centeno A; Pena-Rossi C; Gervitz L; Thangavelu K; St John G; Boklage S; Genovese MC
    RMD Open; 2019; 5(2):e001017. PubMed ID: 31673415
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and adalimumab with methotrexate in patients with rheumatoid arthritis (ORAL Strategy): a phase 3b/4, double-blind, head-to-head, randomised controlled trial.
    Fleischmann R; Mysler E; Hall S; Kivitz AJ; Moots RJ; Luo Z; DeMasi R; Soma K; Zhang R; Takiya L; Tatulych S; Mojcik C; Krishnaswami S; Menon S; Smolen JS;
    Lancet; 2017 Jul; 390(10093):457-468. PubMed ID: 28629665
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Achieving comprehensive disease control in patients with early and established rheumatoid arthritis treated with adalimumab plus methotrexate versus methotrexate alone.
    Keystone EC; Breedveld FC; van der Heijde D; van Vollenhoven RF; Emery P; Smolen JS; Sainsbury I; Florentinus S; Kupper H; Chen K; Kavanaugh A
    RMD Open; 2017; 3(2):e000445. PubMed ID: 29018564
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical consequences of delayed addition of adalimumab to methotrexate therapy over 5 years in patients with rheumatoid arthritis.
    Keystone EC; Kavanaugh A; Weinblatt ME; Patra K; Pangan AL
    J Rheumatol; 2011 May; 38(5):855-62. PubMed ID: 21285171
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical, functional, and radiographic benefits of longterm adalimumab plus methotrexate: final 10-year data in longstanding rheumatoid arthritis.
    Keystone EC; van der Heijde D; Kavanaugh A; Kupper H; Liu S; Guérette B; Mozaffarian N
    J Rheumatol; 2013 Sep; 40(9):1487-97. PubMed ID: 23818718
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Low disease activity for up to 3 years after adalimumab discontinuation in patients with early rheumatoid arthritis: 2-year results of the HOPEFUL-3 Study.
    Tanaka Y; Yamanaka H; Ishiguro N; Miyasaka N; Kawana K; Kimura J; Agata N; Takeuchi T
    Arthritis Res Ther; 2017 Mar; 19(1):56. PubMed ID: 28288682
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of sarilumab monotherapy versus adalimumab monotherapy for the treatment of patients with active rheumatoid arthritis (MONARCH): a randomised, double-blind, parallel-group phase III trial.
    Burmester GR; Lin Y; Patel R; van Adelsberg J; Mangan EK; Graham NM; van Hoogstraten H; Bauer D; Ignacio Vargas J; Lee EB
    Ann Rheum Dis; 2017 May; 76(5):840-847. PubMed ID: 27856432
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Upadacitinib Versus Placebo or Adalimumab in Patients With Rheumatoid Arthritis and an Inadequate Response to Methotrexate: Results of a Phase III, Double-Blind, Randomized Controlled Trial.
    Fleischmann R; Pangan AL; Song IH; Mysler E; Bessette L; Peterfy C; Durez P; Ostor AJ; Li Y; Zhou Y; Othman AA; Genovese MC
    Arthritis Rheumatol; 2019 Nov; 71(11):1788-1800. PubMed ID: 31287230
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled, 52-week trial.
    Keystone EC; Kavanaugh AF; Sharp JT; Tannenbaum H; Hua Y; Teoh LS; Fischkoff SA; Chartash EK
    Arthritis Rheum; 2004 May; 50(5):1400-11. PubMed ID: 15146409
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical and radiographic outcome of a treat-to-target strategy using methotrexate and intra-articular glucocorticoids with or without adalimumab induction: a 2-year investigator-initiated, double-blinded, randomised, controlled trial (OPERA).
    Hørslev-Petersen K; Hetland ML; Ørnbjerg LM; Junker P; Pødenphant J; Ellingsen T; Ahlquist P; Lindegaard H; Linauskas A; Schlemmer A; Dam MY; Hansen I; Lottenburger T; Ammitzbøll CG; Jørgensen A; Krintel SB; Raun J; Johansen JS; Østergaard M; Stengaard-Pedersen K;
    Ann Rheum Dis; 2016 Sep; 75(9):1645-53. PubMed ID: 26489704
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.